Xu, X., Yu, Y., Liu, T., Lv, M., Zhang, H., Ai, L., Cui, Y., Tang, X., Zong, H., Xu, Q., Lin, R., Chen, S. (2026). Tislelizumab plus cetuximab and irinotecan in relapsed/refractory RAS/BRAF wild-type and microsatellite stable metastatic colorectal cancer: A randomized, controlled, multicenter study (TEC2).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.3530